• Lundbeck reported headline results from the Phase IV THRIVE trial of Vyepti in migraine patients who failed a prior CGRP preventive.
• The study showed a majority of continuing participants reported meaningful overall improvement following treatment.
• The drug was generally well tolerated, with no new safety signals flagged in this previously treated population.
• Full trial results will be presented at future scientific congresses, with a peer-reviewed publication planned.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. H. Lundbeck A/S published the original content used to generate this news brief via Cision (Ref. ID: 202610010200BITN____UKPR__EN_20260930-BIT-7538-0) on October 01, 2026, and is solely responsible for the information contained therein.